Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 1/20 | 0.67 |
| ▸ | NT5E | P21589 | 1/20 | 0.61 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.58 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.58 |
| ▸ | TGM2 | P21980 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | HINT1 | P49773 | 1/20 | 0.54 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1477429 | 1.00 | ADORA1 (0.67) | ADORA1NT5ETAS1R3TAS1R1TGM2 | |
| Ribitol SCHEMBL29444994 | 0.93 | ADORA1 (0.59) | ADORA1NT5ETAS1R3TAS1R1TGM2 | |
| SCHEMBL1533806 | 0.93 | NT5E (0.64) | ADORA1NT5ETAS1R3TAS1R1TGM2 | |
| SCHEMBL94114 | 0.93 | NT5E (0.64) | ADORA1NT5ETAS1R3TAS1R1TGM2 | |
| SCHEMBL27126358 | 0.92 | HPGD (0.58) | ADORA1NT5ETAS1R3TAS1R1TGM2 | |
| Cytosine SCHEMBL28900939 | 0.91 | ADORA1 (0.57) | ADORA1NT5ETAS1R3TAS1R1TGM2 | |
| SCHEMBL18521003 | 0.91 | NT5E (0.58) | ADORA1NT5ETAS1R3TAS1R1TGM2 | |
| SCHEMBL2315645 | 0.91 | NT5E (0.69) | NT5ETAS1R3TAS1R1TGM2FUT5 | |
| SCHEMBL31195910 | 0.90 | NT5E (0.56) | ADORA1NT5ETAS1R3TAS1R1TGM2 | |
| Cytidine SCHEMBL29175537 | 0.90 | NT5E (0.57) | ADORA1NT5ETAS1R3TAS1R1TGM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3434773-A2 | MODULATION OF HSP47 EXPRESSION | NITTO DENKO CORPORATION (JP) | 2019-01-30 | — | — | EP | disclosed |
| US-10144928-B2 | Double stranded oligonucleotide compounds comprising positional modifications | QUARK PHARMACEUTICALS, INC. (US) | 2018-12-04 | — | — | US | disclosed |
| US-10093923-B2 | Modulation of HSP47 expression | NITTO DENKO CORPORATION (JP) | 2018-10-09 | — | — | US | disclosed |
| US-10059942-B2 | Therapeutic oligonucleotides comprising pyrazolotriazine nucleotide analogues | BIO-LAB LTD. (IL) | 2018-08-28 | — | — | US | disclosed |
| EP-2855679-B1 | THERAPEUTIC OLIGONUCLEOTIDES COMPRISING PYRAZOLOTRIAZINE NUCLEOTIDE ANALOGUES | QBI ENTPR LTD (IL) | 2018-07-18 | — | — | EP | disclosed |
| EP-2521783-B1 | OLIGONUCLEOTIDE COMPOUNDS COMPRISING NON-NUCLEOTIDE OVERHANGS | QUARK PHARMACEUTICALS INC (US) | 2017-08-09 | — | — | EP | disclosed |
| EP-2585594-B1 | DOUBLE STRANDED RNA COMPOUNDS TO RHOA AND USE THEREOF | QUARK PHARMACEUTICALS INC (US) | 2017-05-31 | — | — | EP | disclosed |
| US-20160355805-A1 | Double Stranded Oligonucleotide Compounds Comprising Positional Modifications | QUARK PHARMACEUTICALS, INC. | 2016-12-08 | — | — | US | disclosed |
| US-20160333354-A1 | DOUBLE STRANDED RNA COMPOUNDS TO RHOA AND USE THEREOF | QUARK PHARMACEUTICALS, INC. (US) | 2016-11-17 | — | — | US | disclosed |
| EP-2649181-B1 | DOUBLE STRANDED OLIGONUCLEOTIDE COMPOUNDS COMPRISING POSITIONAL MODIFICATIONS | QUARK PHARMACEUTICALS INC (US) | 2016-04-27 | — | — | EP | disclosed |
| US-9045755-B2 | Double stranded RNA compounds to RhoA and use thereof | QUARK PHARMACEUTICALS, INC. (US) | 2015-06-02 | — | — | US | disclosed |
| US-8859751-B2 | Oligonucleotide compounds comprising non-nucleotide overhangs | QUARK PHARMACEUTICALS, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-20140235695-A1 | MODULATION OF HSP47 EXPRESSION | NITTO DENKO CORPORATION | 2014-08-21 | — | — | US | disclosed |
| US-8710209-B2 | Modulation of HSP47 expression | NITTO DENKO CORPORATION (JP) | 2014-04-29 | — | — | US | disclosed |
| US-20130324591-A1 | DOUBLE STRANDED OLIGONUCLEOTIDE COMPOUNDS COMPRISING POSITIONAL MODIFICATIONS | QUARK PHARMACEUTICALS, INC. (US) | 2013-12-05 | — | — | US | disclosed |
| US-20130137750-A1 | DOUBLE STRANDED RNA COMPOUNDS TO RHOA AND USE THEREOF | QUARK PHARMACEUTICALS, INC. (US) | 2013-05-30 | — | — | US | disclosed |
| US-20130035368-A1 | OLIGONUCLEOTIDE COMPOUNDS COMPRISING NON-NUCLEOTIDE OVERHANGS | QUARK PHARMACEUTICALS, INC. | 2013-02-07 | — | — | US | disclosed |
| WO-2011084193-A1 | OLIGONUCLEOTIDE COMPOUNDS COMPRISING NON-NUCLEOTIDE OVERHANGS | QUARK PHARMACEUTICALS, INC. (US) | 2011-07-14 | — | — | WO | disclosed |
| US-5840705-A | CONTAINING NUCLEOTIDE, NUCLEOSIDE AND/OR NUCLEIC ACID-DERIVED BASE AS ENZYME INHIBITOR; TREATING DIABETES, OBESITY | THE HOKUREN FEDERATION OF AGRICULTURAL COOPERATIVES (JP) | 1998-11-24 | — | — | US | disclosed |
| EP-0738475-A1 | Alpha-glucosidase inhibitor, composition principally comprising sugar and containing the same, sweetener, food and feed | THE HOKUREN FEDERATION OF AGRICULTURAL COOPERATIVES (JP) | 1996-10-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035368-A1 | OLIGONUCLEOTIDE COMPOUNDS COMPRISING NON-NUCLEOTIDE OVERHANGS | DCLRE1B, SNRPE, UPF1 | ADORA1 1401/4885NT5E 183/4885TAS1R3 3038/4885 |
| US-10093923-B2 | Modulation of HSP47 expression | HSPA1A, HSPH1, HSPA8 | ADORA1 4226/4885NT5E 3596/4885TAS1R3 3411/4885 |
| US-10059942-B2 | Therapeutic oligonucleotides comprising pyrazolotriazine nucleotide analogues | RNASEH1, RNGTT, EIF2AK2 | ADORA1 1019/4885NT5E 222/4885TAS1R3 3130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.